{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T06:27:47Z","timestamp":1762928867505,"version":"build-2065373602"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.mehy.2021.110486","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T03:49:42Z","timestamp":1610077782000},"page":"110486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Scientific hypothesis and rational pharmacological for the use of sacubitril\/valsartan in cardiac damage caused by COVID-19"],"prefix":"10.1016","volume":"147","author":[{"given":"Antonio","family":"Vitiello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"La Porta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.mehy.2021.110486_b0005","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMoa2005412","article-title":"Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington","volume":"382","author":"McMichael","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2021.110486_b0010","first-page":"1","article-title":"Remdesivir and COVID-19","volume":"17","author":"Ferrara","year":"2020","journal-title":"Ir J Med Sci."},{"key":"10.1016\/j.mehy.2021.110486_b0015","unstructured":"World health organization (WHO) https:\/\/www.who.int\/emergencies\/diseases\/novel coronavirus2019\/situation-reports (Situation Reports July 2020)."},{"key":"10.1016\/j.mehy.2021.110486_b0020","unstructured":"Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus. 2020 Oct In: StatPearls [Internet]."},{"issue":"2","key":"10.1016\/j.mehy.2021.110486_b0025","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.mehy.2021.110486_b0030","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/s41379-020-0536-x","article-title":"Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies","volume":"33","author":"Tian","year":"2020","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.mehy.2021.110486_b0035","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/ajcp\/aqaa062","article-title":"COVID-19 Autopsies, Oklahoma, USA","volume":"153","author":"Barton","year":"2020","journal-title":"Am J Clin Pathol."},{"issue":"7","key":"10.1016\/j.mehy.2021.110486_b0040","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/jamacardio.2020.0950","article-title":"Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China","volume":"5","author":"Shi","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"7","key":"10.1016\/j.mehy.2021.110486_b0045","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jamacardio.2020.1017","article-title":"Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)","volume":"5","author":"Guo","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"5","key":"10.1016\/j.mehy.2021.110486_b0050","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","volume":"46","author":"Ruan","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.mehy.2021.110486_b0055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijid.2020.03.017","article-title":"Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis","volume":"94","author":"Yang","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"7","key":"10.1016\/j.mehy.2021.110486_b0060","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/jamacardio.2020.0950","article-title":"Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhanm, China","volume":"5","author":"Shi","year":"2020","journal-title":"JAMA Cardiol."},{"issue":"2","key":"10.1016\/j.mehy.2021.110486_b0065","first-page":"88","article-title":"Cytokine storm and colchicine potential role in fighting SARS-CoV-2 pneumonia","volume":"14","author":"Vitiello","year":"2020","journal-title":"Italian J Med"},{"issue":"11","key":"10.1016\/j.mehy.2021.110486_b0070","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s00228-020-02947-4","article-title":"The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2: Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?","volume":"76","author":"Ferrara","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.mehy.2021.110486_b0075","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1161\/01.RES.81.4.493","article-title":"Interleukin-1 beta inhibits phospholamban gene expression in cultured cardiomyocytes","volume":"81","author":"McTiernan","year":"1997","journal-title":"Circ Res."},{"issue":"17","key":"10.1016\/j.mehy.2021.110486_b0080","doi-asserted-by":"crossref","first-page":"6753","DOI":"10.1073\/pnas.86.17.6753","article-title":"Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness","volume":"86","author":"Gulick","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.mehy.2021.110486_b0085","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1128\/MMBR.05015-11","article-title":"Into the Eye of the Cytokine Storm","volume":"76","author":"Tisoncik","year":"2012","journal-title":"Microbiol Mol Biol Rev"},{"issue":"5","key":"10.1016\/j.mehy.2021.110486_b0090","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00281-017-0629-x","article-title":"Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology","volume":"39","author":"Channappanavar","year":"2017","journal-title":"Semin Immunopathol"},{"issue":"10223","key":"10.1016\/j.mehy.2021.110486_b0095","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"The Lancet"},{"issue":"5","key":"10.1016\/j.mehy.2021.110486_b0100","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00281-017-0629-x","article-title":"Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology","volume":"39","author":"Channappanavar","year":"2017","journal-title":"Semin Immunopathol."},{"issue":"5","key":"10.1016\/j.mehy.2021.110486_b0105","doi-asserted-by":"crossref","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality","volume":"55","author":"Zhang","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.mehy.2021.110486_b0110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.virusres.2007.02.014","article-title":"Human immunopathogenesis of severe acute respiratory syndrome (SARS)","volume":"133","author":"Cameron","year":"2008","journal-title":"Virus Res"},{"issue":"3","key":"10.1016\/j.mehy.2021.110486_b0115","doi-asserted-by":"crossref","first-page":"L217","DOI":"10.1152\/ajplung.00311.2013","article-title":"The mercurial nature of neutrophils: still an enigma in ARDS?","volume":"306","author":"Williams","year":"2014","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.mehy.2021.110486_b0120","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cytogfr.2020.05.003","article-title":"The cytokine storm in COVID-19: An overview of the involvement of the chemokine\/chemokine-receptor system","volume":"53","author":"Coperchini","year":"2020","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"10.1016\/j.mehy.2021.110486_b0125","first-page":"R265","article-title":"Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility","volume":"276","author":"Kumar","year":"1999","journal-title":"Am J Physiol"},{"issue":"5","key":"10.1016\/j.mehy.2021.110486_b0130","doi-asserted-by":"crossref","first-page":"R1900","DOI":"10.1152\/ajpregu.00146.2006","article-title":"Nitric oxide-dependent and -independent mechanisms are involved in TNF-alpha -induced depression of cardiac myocyte contractility","volume":"292","author":"Kumar","year":"2007","journal-title":"Am J Physiol Regul Integr Comp Physiol."},{"issue":"1","key":"10.1016\/j.mehy.2021.110486_b0135","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.bbadis.2006.09.002","article-title":"NO-cGMP and TNF-alpha counter regulatory system in blood: understanding the mechanisms leading to myocardial dysfunction and failure","volume":"1772","author":"Elahi","year":"2007","journal-title":"Biochim Biophys Acta."},{"issue":"9","key":"10.1016\/j.mehy.2021.110486_b0140","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1172\/JCI29134","article-title":"TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways","volume":"117","author":"Haudek","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"14","key":"10.1016\/j.mehy.2021.110486_b0145","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1161\/01.CIR.97.14.1382","article-title":"Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats","volume":"97","author":"Bozkurt","year":"1998","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.mehy.2021.110486_b0150","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1161\/01.RES.81.4.627","article-title":"Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha","volume":"81","author":"Kubota","year":"1997","journal-title":"Circ Res"},{"issue":"9","key":"10.1016\/j.mehy.2021.110486_b0155","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1172\/JCI29134","article-title":"TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways","volume":"117","author":"Haudek","year":"2007","journal-title":"J Clin Invest."},{"issue":"4","key":"10.1016\/j.mehy.2021.110486_b0160","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00024382-200210000-00012","article-title":"IL-1beta and IL-6 act synergistically with TNF-alpha to alter cardiac contractile function after burn trauma","volume":"18","author":"Maass","year":"2002","journal-title":"Shock."},{"issue":"18","key":"10.1016\/j.mehy.2021.110486_b0165","doi-asserted-by":"crossref","first-page":"16304","DOI":"10.1074\/jbc.M212321200","article-title":"JAK2\/STAT3, Not ERK1\/2, Mediates Interleukin-6-induced Activation of Inducible Nitric-oxide Synthase and Decrease in Contractility of Adult Ventricular Myocytes","volume":"278","author":"Yu","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.mehy.2021.110486_b0170","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1161\/01.RES.0000150734.79804.92","article-title":"Cytokine-Induced Modulation of Cardiac Function","volume":"95","author":"Prabhu","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.mehy.2021.110486_b0175","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ejmech.2019.07.033","article-title":"Protective effect of piceatannol and bioactive stilbene derivatives against hypoxia-induced toxicity in H9c2 cardiomyocytes and structural elucidation as 5-LOX inhibitors","volume":"180","author":"Boccellino","year":"2019","journal-title":"Eur J Med Chem"},{"issue":"9-10","key":"10.1016\/j.mehy.2021.110486_b0180","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.2119\/molmed.2011.00100","article-title":"Altered Oxido-Reductive State in the Diabetic Heart: Loss of Cardioprotection due to Protein Disulfide Isomerase","volume":"17","author":"Toldo","year":"2011","journal-title":"Mol Med"},{"key":"10.1016\/j.mehy.2021.110486_b0185","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.peptides.2012.12.010","article-title":"C-type natriuretic peptide: A new cardiac mediator","volume":"40","author":"Del Ry","year":"2013","journal-title":"Peptides"},{"issue":"1","key":"10.1016\/j.mehy.2021.110486_b0190","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/sj.bjp.0707476","article-title":"C-type natriuretic peptide and endothelium-dependent hyperpolarization in the guinea-pig carotid artery","volume":"153","author":"Leuranguer","year":"2008","journal-title":"Br J Pharmacol."},{"issue":"8","key":"10.1016\/j.mehy.2021.110486_b0195","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.peptides.2011.06.014","article-title":"Expression of C-type natriuretic peptide and its receptor NPR-B in cardiomyocytes","volume":"32","author":"Del Ry","year":"2011","journal-title":"Peptides"},{"issue":"1","key":"10.1016\/j.mehy.2021.110486_b0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/bbrc.1996.0836","article-title":"C-Type Natriuretic Peptide as an Autocrine\/Paracrine Regulator of Osteoblast","volume":"223","author":"Suda","year":"1996","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.mehy.2021.110486_b0205","doi-asserted-by":"crossref","unstructured":"K. Totsune K. Takahashi O. Murakami F. Satoh M. Sone M. Ohneda Y. Miura T. Mouri Immunoreactive brain natriuretic peptide in human adrenal glands and adrenal tumors 135 3 1996 352 356 10.1530\/eje.0.1350352.","DOI":"10.1530\/eje.0.1350352"},{"issue":"1","key":"10.1016\/j.mehy.2021.110486_b0210","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bbrc.2007.02.085","article-title":"CNP infusion attenuates cardiac dysfunction and inflammation in myocarditis","volume":"356","author":"Obata","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.mehy.2021.110486_b0215","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jacc.2004.10.067","article-title":"C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction","volume":"45","author":"Soeki","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.mehy.2021.110486_b0220","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/art.38199","article-title":"Protective Effects of C\u2010Type Natriuretic Peptide on Linear Growth and Articular Cartilage Integrity in a Mouse Model of Inflammatory Arthritis","volume":"66","author":"B\u00fck\u00fclmez","year":"2014","journal-title":"Arthritis & Rheumatology"},{"issue":"2","key":"10.1016\/j.mehy.2021.110486_b0225","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1021\/bm501575w","article-title":"Controlled Release of C-Type Natriuretic Peptide by Microencapsulation Dampens Proinflammatory Effects Induced by IL-1\u03b2 in Cartilage Explants","volume":"16","author":"Peake","year":"2015","journal-title":"Biomacromolecules"},{"issue":"2","key":"10.1016\/j.mehy.2021.110486_b0230","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jss.2014.11.023","article-title":"C-type natriuretic peptide attenuates lipopolysaccharide-induced acute lung injury in mice","volume":"194","author":"Kimura","year":"2015","journal-title":"J Surg Res"},{"key":"10.1016\/j.mehy.2021.110486_b0235","doi-asserted-by":"crossref","unstructured":"T. Horio T. Tokudome T. Maki F. Yoshihara S.-I. Suga T. Nishikimi M. Kojima Y. Kawano K. Kangawa Gene Expression, Secretion, and Autocrine Action of C-Type Natriuretic Peptide in Cultured Adult Rat Cardiac Fibroblasts 144 6 2003 2279 2284 10.1210\/en.2003-0128.","DOI":"10.1210\/en.2003-0128"},{"key":"10.1016\/j.mehy.2021.110486_b0240","doi-asserted-by":"crossref","unstructured":"ZHI.-QIANG. LI YING.-LONG. LIU GANG LI BIN LI YANG LIU XIAO.-FENG. LI AI.-JUN. LIU Inhibitory effects of C-type natriuretic peptide on the differentiation of cardiac fibroblasts, and secretion of monocyte chemoattractant protein-1 and plasminogen activator inhibitor-1 11 1 2015 159 165 10.3892\/mmr.2014.2763.","DOI":"10.3892\/mmr.2014.2763"},{"issue":"5","key":"10.1016\/j.mehy.2021.110486_b0245","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1165\/rcmb.2011-0115OC","article-title":"Periostin, a Matricellular Protein, Plays a Role in the Induction of Chemokines in Pulmonary Fibrosis","volume":"46","author":"Uchida","year":"2012","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"10.1016\/j.mehy.2021.110486_b0250","article-title":"Erratum to: C-type natriuretic peptide ameliorates pulmonary fibrosis by acting on lung fibroblasts in mice","volume":"17","author":"Kimura","year":"2016","journal-title":"Respir Res"},{"key":"10.1016\/j.mehy.2021.110486_b0255","doi-asserted-by":"crossref","first-page":"5858315","DOI":"10.1155\/2017\/5858315","article-title":"A Novel Role for Brain Natriuretic Peptide: Inhibition of IL-1\u03b2 Secretion via Downregulation of NF-kB\/Erk 1\/2 and NALP3\/ASC\/Caspase-1 Activation in Human THP-1 Monocyte","volume":"2017","author":"Mezzasoma","year":"2017","journal-title":"Mediators Inflamm."},{"issue":"9380","key":"10.1016\/j.mehy.2021.110486_b0260","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0140-6736(03)13976-1","article-title":"B-type natriuretic peptide in cardiovascular disease","volume":"362","author":"de Lemos","year":"2003","journal-title":"The Lancet"},{"issue":"7","key":"10.1016\/j.mehy.2021.110486_b0265","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/jamacardio.2020.0950","article-title":"Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China","volume":"5","author":"Shi","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"7","key":"10.1016\/j.mehy.2021.110486_b0270","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jamacardio.2020.1017","article-title":"Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)","volume":"5","author":"Guo","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10.1016\/j.mehy.2021.110486_b0275","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/resp.13233","article-title":"Pneumonia as a cardiovascular disease: Pneumonia-related cardiac damage","volume":"23","author":"Restrepo","year":"2018","journal-title":"Respirology"},{"key":"10.1016\/j.mehy.2021.110486_b0280","unstructured":"Chen C, Zhang XR, Ju ZY, He WF. Advances in the research of mechanism and related immunotherapy on the cytokine storm induced by coronavirus disease 2019]. Zhonghua Shao Shang Za Zhi. 2020 Jun 20;36(6):471-475. Chinese. doi: 10.3760\/cma.j.cn501120-20200224-00088."},{"key":"10.1016\/j.mehy.2021.110486_b0285","doi-asserted-by":"crossref","first-page":"118510","DOI":"10.1016\/j.lfs.2020.118510","article-title":"Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19","volume":"262","author":"Vitiello","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.mehy.2021.110486_b0290","unstructured":"Wei ZY, Qian HY. [Myocardial injury in patients with COVID-19 pneumonia]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Mar 2;48(0):E006. Chinese. doi: 10.3760\/cma.j.issn.cn112148-20200220-00106."},{"issue":"6","key":"10.1016\/j.mehy.2021.110486_b0295","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1136\/hrt.2005.071233","article-title":"Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine","volume":"92","author":"Weber","year":"2006","journal-title":"Heart"},{"issue":"4","key":"10.1016\/j.mehy.2021.110486_b0300","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.mehy.2021.110486_b0305","unstructured":"Santos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M et al. The ACE2\/Angiotensin-(1-7)\/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7)."},{"issue":"8","key":"10.1016\/j.mehy.2021.110486_b0310","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1161\/CIRCRESAHA.116.307708","article-title":"Role of the ACE2\/Angiotensin 1\u20137 Axis of the Renin\u2013Angiotensin System in Heart Failure","volume":"118","author":"Patel","year":"2016","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.mehy.2021.110486_b0315","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-020-01352-w","article-title":"Prognostic value of NT-proBNP in patients with severe COVID-19","volume":"21","author":"Gao","year":"2020","journal-title":"Respir Res"},{"issue":"11","key":"10.1016\/j.mehy.2021.110486_b0320","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/CIRCULATIONAHA.115.018622","article-title":"Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition","volume":"133","author":"Hubers","year":"2016","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.mehy.2021.110486_b0325","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.atherosclerosis.2006.10.013","article-title":"Angiotensin II induces IL-6 expression and the Jak-STAT3 pathway in aortic adventitia of LDL receptor-deficient mice","volume":"194","author":"Recinos","year":"2007","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.mehy.2021.110486_b0330","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1161\/ATVBAHA.111.237198","article-title":"Macrophage Polarization by Angiotensin II-Type 1 Receptor Aggravates Renal Injury-Acceleration of Atherosclerosis","volume":"31","author":"Yamamoto","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.1016\/j.mehy.2021.110486_b0335","doi-asserted-by":"crossref","first-page":"173373","DOI":"10.1016\/j.ejphar.2020.173373","article-title":"Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?","volume":"883","author":"Vitiello","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.mehy.2021.110486_b0340","doi-asserted-by":"crossref","unstructured":"Mariarosaria Boccellino Marina Di Domenico Maria Donniacuo Giuseppe Bitti Giulia Gritti Pasqualina Ambrosio Lucio Quagliuolo Barbara Rinaldi Elena Cavarretta AT1-receptor blockade: Protective effects of irbesartan in cardiomyocytes under hypoxic stress PLoS ONE 13 10 e0202297 10.1371\/journal.pone.0202297.g003.","DOI":"10.1371\/journal.pone.0202297"},{"issue":"2","key":"10.1016\/j.mehy.2021.110486_b0345","first-page":"114","article-title":"Antirheumatic in SARS-CoV-2: benefit or risk?","volume":"14","author":"Ferrara","year":"2020","journal-title":"Italian Journal of Medicine."},{"issue":"4","key":"10.1016\/j.mehy.2021.110486_b0350","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1165\/rcmb.2012-0451OC","article-title":"Angiotensin-Converting Enzyme 2\/Angiotensin-(1-7)\/Mas Axis Protects against Lung Fibrosis by Inhibiting the MAPK\/NF-\u03baB Pathway","volume":"50","author":"Meng","year":"2014","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.mehy.2021.110486_b0355","doi-asserted-by":"crossref","first-page":"105579","DOI":"10.1016\/j.ejps.2020.105579","article-title":"Therapeutic Strategies for SARS-CoV-2 acting on ACE-2","volume":"156","author":"Vitiello","year":"2021","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"10.1016\/j.mehy.2021.110486_b0360","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1161\/01.CIR.0000081768.13378.BF","article-title":"Activation and functional significance of the renin-angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor","volume":"108","author":"Flesch","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.mehy.2021.110486_b0365","doi-asserted-by":"crossref","unstructured":"Domenico Acanfora Marco Matteo Ciccone Pietro Scicchitano Chiara Acanfora Gerardo Casucci Sacubitril\/valsartan in COVID-19 patients: the need for trials 6 4 2020 2020 253 254 10.1093\/ehjcvp\/pvaa044.","DOI":"10.1093\/ehjcvp\/pvaa044"},{"key":"10.1016\/j.mehy.2021.110486_b0370","doi-asserted-by":"crossref","unstructured":"Antonio Vitiello Raffaele La Porta Francesco Ferrara Sacubitril, valsartan and SARS-CoV-2 bmjebm-2020-111497 10.1136\/bmjebm-2020-111497.","DOI":"10.22541\/au.159301795.58749374"},{"issue":"4","key":"10.1016\/j.mehy.2021.110486_b0375","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/08998280.2018.1499293","article-title":"Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia","volume":"31","author":"Henry","year":"2018","journal-title":"Baylor University Medical Center Proceedings"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987721000049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987721000049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:22:11Z","timestamp":1759692131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987721000049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":75,"alternative-id":["S0306987721000049"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2021.110486","relation":{},"ISSN":["0306-9877"],"issn-type":[{"type":"print","value":"0306-9877"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Scientific hypothesis and rational pharmacological for the use of sacubitril\/valsartan in cardiac damage caused by COVID-19","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2021.110486","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110486"}}